v3.20.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Oct. 31, 2020
Nov. 02, 2019
Cash flows from operating activities:    
Net loss $ (293,834) $ (188,282)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 149,922 112,662
Share-based compensation 182,060 189,036
Amortization of acquired intangible assets 333,934 253,467
Amortization of inventory fair value adjustment associated with acquisitions 17,284 3,316
Restructuring related impairment charges 123,559 16,243
Other expense, net 23,080 14,814
Changes in assets and liabilities:    
Accounts receivable 2,075 8,374
Inventories 29,817 (30,602)
Prepaid expenses and other assets (8,692) (11,039)
Accounts payable 34,768 30,801
Accrued liabilities and other non-current liabilities 26,817 (106,258)
Accrued employee compensation 38,202 11,927
Net cash provided by operating activities 658,992 304,459
Cash flows from investing activities:    
Sales of available-for-sale securities 0 18,832
Purchases of technology licenses (8,476) (1,936)
Purchases of property and equipment (88,242) (62,935)
Cash payment for acquisition, net of cash and cash equivalents acquired 0 (477,579)
Other, net 223 (1,793)
Net cash used in investing activities (96,495) (525,411)
Cash flows from financing activities:    
Repurchases of common stock (25,202) (64,272)
Proceeds from employee stock plans 50,490 103,109
Tax withholding paid on behalf of employees for net share settlement (82,626) (80,862)
Dividend payments to shareholders (120,111) (119,496)
Payments on technology license obligations (76,794) (57,213)
Proceeds from issuance of debt 0 350,000
Principal payments of debt (100,000) (50,000)
Payment of debt financing costs (22,313) 0
Other, net (1,504) (4,355)
Net cash provided by (used in) financing activities (378,060) 76,911
Net increase (decrease) in cash and cash equivalents 184,437 (144,041)
Cash and cash equivalents at beginning of period 647,604 582,410
Cash and cash equivalents at end of period $ 832,041 $ 438,369